ArticleAlzheimer's research & therapy2026
Independent and interactive contributions of white matter hyperintensities and Alzheimer's disease imaging and plasma biomarkers to cognitive decline in older adults without dementia.
Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccounting for common co-pathologies such as white matter hyperintensities (WMH) may improve the prognostic performance of imaging and blood-based biomarkers for cognitive decline in Alzheimer’s disease (AD). Plasma biomarkers including p-tau217, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) as well as imaging biomarkers including hippocampus volume, amyloid-β (Aβ) PET, and WMH have been reported to be associated with decline across multiple cognitive domains. However, a comprehensive comparison of these biomarkers in predicting domain-specific cognitive decline and their potential additive or interactive effects with WMH volume, is lacking.
methodsWe analyzed data from 216 (median age [range]: 67.2 years [51–90]) community-dwelling older adults who underwent MRI, Aβ PET, and blood-based biomarker assessments. Participants were followed for a median of 5.3 years with annual clinical and neuropsychological evaluations. We created cognitive composite scores for episodic memory, executive functions, processing speed/attention, language, visuospatial abilities, and global cognition. Linear mixed-effects models were used to compare the predictive value of imaging and blood-based biomarkers individually and in interaction with WMH volume for decline across cognitive domains and clinical dementia rating-sum of boxes (CDR-SOB) progression. Multigroup path analysis was used to investigate multiple biomarker interactions simultaneously.
resultsIndividual biomarkers significantly predict decline across multiple cognitive domains. WMHs independently predicted decline in processing speed/attention (β = -0.024, 95% CI -0.045 to -0.004, P = 0.022) and executive functions (β = -0.025, 95% CI -0.042 to -0.007, P = 0.005) and interacted with imaging and plasma biomarkers to accelerate cognitive decline across nearly all domains, with the strongest effect observed in episodic memory (β = -0.042, 95% CI -0.057 to -0.027, P < 0.001). Additionally, significant progression in the CDR-SOB was only observed in individuals with both elevated Aβ and WMH volume. Multigroup path analysis identified the interaction between Aβ PET and WMH volume as the most robust interaction associated with faster decline.
conclusionsCoexisting AD pathology and WMHs interacted to predict faster cognitive decline, most pronounced in episodic memory but also across other cognitive domains. Aβ PET was the main factor interacting with WMHs to predict episodic memory decline, but significant interactions were also observed for hippocampal volume, plasma p-tau217, and GFAP. Consideration of Aβ PET and blood-based biomarkers in the context of an individual’s WMH volume may improve the prognostic value of these biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.